<DOC>
	<DOCNO>NCT02095509</DOCNO>
	<brief_summary>To evaluate pharmacokinetics thromboprophylactic agent enoxaparin critically ill patient compare plasma anti-factor Xa activity enoxaparin administer either continuous intravenous infusion subcutaneous bolus daily . To investigate possible ongoing coagulation coagulation marker antithrombotic therapy standard dose enoxaparin</brief_summary>
	<brief_title>Pharmacokinetics Enoxaparin Intensive Care Patients</brief_title>
	<detailed_description />
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<criteria>Body Mass Index 1830 kg/m2 Critically ill patient require intensive care pharmacological thromboprophylaxis Expected remain ICU least 72 h Written inform consent obtain patient his/her legal representative . Other indication anticoagulant therapy thromboprophylaxis Intracranial haemorrhage central neurosurgical operation within three month prior admission Disseminated intravascular coagulation ( DIC ) accord international society Thrombosis Haemostasis criterion Known heparin induce thrombocytopenia ( HIT ) , hypersensitivity enoxaparin heparin Treatment enoxaparin lowmolecular weight heparin ( LMWH ) heparin within 24 hour prior ICU admission . If patient receive thromboprophylactic dose LMWH within 2472 hour ICU admission inclusion do measure antifactor Xa level &lt; 0.1 IU/ml time admission Any longterm anticoagulant medication , expect lowdose aspirin Major bleeding within last week unless definitively treat Blood platelet count &lt; 50 , Pthromboplastin time ( TT ) &lt; 40 % , international normalize ratio ( INR ) &gt; 1.7 Glomerular filtration rate le 50 ml/min/1.73 m2 estimate serum creatinine apply CockcroftGault equation chronic dialysis HIV , hepatitis B virus , hepatitis C virus infection Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>